Drug profile · INN
memantine
APO-MEMANTINE
memantine (APO-MEMANTINE) is a glutamate [nmda] receptor negative allosteric modulator. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Nervous system (N06) N06DX01
Patents linked 1
Pipeline programs 5
News articles 0
Drug details — memantine
- Class
- Nervous system (N06)
- Route
- —
- Patents
- 1
- Programs
- 5
- Data quality
- 0.83
Quick answer
memantine (APO-MEMANTINE) is a glutamate [nmda] receptor negative allosteric modulator. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN memantine
Brand APO-MEMANTINE
Mechanism Glutamate [NMDA] receptor negative allosteric modulator
Therapeutic class Nervous system (N06)
ATC code N06DX01
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Glutamate [NMDA] receptor negative allosteric modulator
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is memantine?
memantine (APO-MEMANTINE) is a glutamate [nmda] receptor negative allosteric modulator. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for memantine?
APO-MEMANTINE is a marketed brand name for memantine. Check FDA Drugs@FDA for the current US label holder and prescribing information.